CanSino Biologics issued an announcement stating that the company has been closely monitoring recent market developments in mRNA technology. The mRNA platform is one of the key technological areas the company is focusing on. Currently, the company is conducting research and development of mRNA preventive vaccines and therapeutic biological products, while also advancing the development of related delivery systems. In the therapeutic field, the company is advancing research on mRNA vaccines for indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of InVivoCAR-related therapies. All these projects are currently in their early stages.